loader image
Thursday, December 7, 2023
68 F
McAllen
We Welcome your Press Release
- Advertisement -

Human Polyclonal Antibody to Treat Unvaccinated Non-Hospitalized Adult Patients

Translate to Spanish or other 102 languages!

Enrollment in this study is voluntary and the patients will not be charged for this treatment and/or the follow-up. Image for illustration purposes.
Enrollment in this study is voluntary and the patients will not be charged for this treatment and/or the follow-up. Image for illustration purposes.

Mega Doctor News

- Advertisement -

EDINBURG, Texas – DHR Health is involved in a new and innovative study to use human polyclonal antibody to treat non-hospitalized patients who are >18 years of age with mild-moderate COVID-19. Safety of this human polyclonal antibody (SAB-185) has already been established. This would be the first such study in which human polyclonal antibodies will be used to treat patients with COVID-19.

“We are embarking on a new study that is FDA-approved and NIH-funded to infuse human polyclonal antibodies in non-hospitalized unvaccinated high-risk individuals who are COVID-19 positive” said Sohail Rao, MD, MA, DPhil, President & CEO, DHR Health Institute for Research & Development. “The human polyclonal antibody has been shown to neutralize both wild-type and various variants of SARS-CoV-2 virus including Delta. the primary objective of this study is to prevent hospitalization of the patients with COVID-19.”

The study entails a single treatment with either REGEN-COV monoclonal antibody or SAB-185 human polyclonal antibody which is infused intravenously. Enrollment in this study is voluntary and the patients will not be charged for this treatment and/or the follow-up. To learn more about who would qualify for this treatment, please visit this weblink: https://youtu.be/u8lubUkucNY or call COVID-19 treatment hotline (956) 362-2393 (9:00 a.m. – 5:00 p.m.; M-F) or (956) 342-2383 for more information.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Use Of Anticoagulant Drug After Aortic Valve Replacement Lowers Mortality Risk

The use of bioprosthetic aortic valve replacement has increased significantly during the past decade.

Salood Joins Driscoll to Deliver Non-Medical Financial Aid to Child Cancer Patients

The aid will go to indirect healthcare expenses including mortgage, utilities, lodging, food, and more

Medicare is Overpaying for Generic Drugs

The researchers found evidence that the private insurers that sponsor Medicare Part D are artificially inflating the costs of certain generic drugs by overpaying pharmacies.
- Advertisement -
×